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Background: Discontinuation of oral antiplatelet therapy (OAT) is associated with an increased risk of adverse cardiac events, particularly after 
drug-eluting stents (DES) implantation.
Aim: to determine the prevalence and predictors of discontinuation of OAT after DES implantation and to evaluate its effects on long-term prognosis.
Methods: A prospective observational cohort study was conducted on 1358 consecutive patients (pts), successfully treated with DES and 
discharged on dual OAT with aspirin (100 mg/day) and clopidogrel (75 mg/day). Clopidogrel was maintained for at least 12 months. Pts were 
followed-up for 32.4±11.3 months. Prevalence and predictors of aspirin and/or clopidogrel discontinuation were assessed. Major adverse cardiac 
events (MACE), defined as death, acute coronary syndrome leading to hospitalization, and non-fatal stroke were recorded. All cause death, definite, 
probable, and possible stent thrombosis (ST), and TIMI major and minor bleeding were also recorded.
Results: A total of 8.8% of pts discontinued one or both antiplatelet agents within the first 12 months (early discontinuation) and 4.8% 
withdrew aspirin after 1 year (late discontinuation). Pts who discontinued OAT had a higher incidence of death (9.2% vs 4.9%, p=0.01), MACE 
(25.5% vs 13.3%, p<0.001), ST (7.1% vs 3.2%, p=0.01), major (16.8% vs 1.3%, p<0.001), and minor bleeding (26.8% vs 5.2%, p<0.001). Death 
(13.4% vs 4.7%, p<0.001), MACE (28.6% vs 13.7%, p<0.001), and ST (7.6% vs 3.4%, p=0.038) were associated only with early discontinuation. 
Discontinuation was predicted by a history of prior stroke (OR=3.82, p<0.001), statins (OR=0.35, p<0.001), and oral anticoagulants at discharge 
(OR=5.94, p<0.001), in-hospital major (OR=7.69, p<0.001), and minor bleeding (OR=2.17, p=0.028). The independent predictors of early 
discontinuation were in-hospital major bleeding (OR=9.00, p<0.001), statins (OR=0.36, p<0.001), and oral anticoagulants at discharge (OR=8.21, 
p<0.001). Late discontinuation was predicted only by history of prior stroke (OR=5.21, p<0.001).
Conclusions: Early discontinuation of OAT is associated with increased overall mortality, MACE, and ST.
